Healthcare >> Sector Roundtables >> July 28, 2003
THOMAS SHRADER joined Harris Nesbitt Gerard in 2001 (then Gerard Klauer
Mattison) as a Research Analyst in the Healthcare Group, focusing on
biotechnology. Previously, he had been a Vice President of Equity
Research in Biotechnology at Tucker Anthony Sutro. His prior experience
includes research analysis at Oscar Gruss & Son and eight years as a
Professor of Biochemistry at the Albert Einstein College of Medicine. He
holds a degree in Biophysics from Johns Hopkins University and earned
his PhD in Molecular Biophysics and Biochemistry at Yale University. As
a Helen Hay Whitney Postdoctoral Fellow in Biology at the Massachusetts
Institute of Technology, he conducted research in Molecular Genetics. Profile
MICHAEL G. KING is a Managing Director and Senior Equity Research
Analyst in the Health Care Group at Banc of America Securities LLC where
he covers the biotechnology sector. He joined Banc of America Securities
in 2002 from Robertson Stephens, where he had been a Managing Director
and Senior Biotechnology Analyst since 1998. Prior to that, he served as
Senior Biotechnology Analyst at Vector Securities from 1996 to 1998 and
at Dillon, Read & Co. from 1994 to 1996. He has also held positions at
D. Blech & Company, Alex. Brown and Sons, Hambrecht & Quist and Kidder,
Peabody & Company. He earned a BBA with honors in Finance from Baruch
College. He was ranked fourth for his stock-picking accuracy in The Wall
Street Journal's annual 'Best on the Street' survey in 2001 and was
given the Institutional Investor Home-Run Hitter award in 2000 for his
coverage of OSI Pharmaceuticals. Profile
JENNIFER M. CHAO is a Senior Analyst and Managing Director at RBC
Capital Markets. Prior to joining RBC Capital Markets, Ms. Chao was a
Senior Analyst at Leerink Swann & Co. Ms. Chao's industry experience
includes research at the Columbia Neurological Institute and the Harvard
School of Public Health. Ms. Chao was also a research fellow at Harvard
Medical School/Massachusetts General Hospital-Department of Medicine as
a Biomedical Research Career Award fellow. Ms. Chao received her BA
degree in Politics and Greek Classics at New York University and
completed a Post-Baccalaureate program in Health Sciences-Genetics at
Harvard University. Profile
ERIC SCHMIDT is a Managing Director and Senior Research Analyst at SG
Cowen Securities. He joined SG Cowen in 1998 and has been covering
biotechnology stocks for eight years. He was a runner-up in
biotechnology in the 2001 and 2002 Institutional Investor survey. He was
previously a Vice President and Research Analyst for UBS Securities.
Before joining UBS, he co-founded Cambridge Biological Consultants, a
scientific consulting and research firm. He holds a BA in Chemistry from
the University of Pennsylvania and a PhD in Biochemistry from the
Massachusetts Institute of Technology. Profile
Ms. Chao: Year to date the sector has performed exceedingly well. Using
the two major biotech indices, namely the NASDAQ
